

Zydus Cadila receives tentative approval for Doxepin Hcl tablets

Ahmedabad, 27 February 2013

Zydus Cadila has received tentative approval for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg from the USFDA.

The estimated sales in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment, was USD 15.5 million. It is scheduled to be launched in June 2020 upon patent expiry.

The group now has 77 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04.
